clinical trial · NCT04434092
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
Hoffmann-La Roche·phase3·active not recruiting·n = 210
Paroxysmal Nocturnal HemoglobinuriaCrovalimabEculizumab
brief summary
A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.
started
Oct 8, 2020
primary completion
Nov 16, 2022
completion
Sep 30, 2027
last updated
Feb 17, 2026
official title
A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol